Rui-Li Zhang

Rui-Li Zhang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RZRui-Li Zhang
Rui-Li Zhang
QWQianqiu Wang
Qianqiu Wang
JZJin-Ping Zhang
Jin-Ping Zhang
LYLi-Jia Yang
Li-Jia Yang
Serofast, a persistent nontreponemal serological response observed in early syphilis patients after conventional treatment, remains a concern of clinicians and syphilis patients. No consensus has been established, however, that defines an effective treatment strategy and clarifies the pathogenesis. In this study, 517 patients with early syphilis were enrolled and treated. Twelve months after treatment, 79.3% (410/517) of patients achieved serological cure, 20.1% (104/517) were serofast, and 0.6% (3/517) were serological failures. Multivariate analysis demonstrated that older age (>40 years) and lower baseline RPR titer (≤ 1:8) were associated with serofast status. We also identified 21 T. pallidum molecular subtypes among early syphilis patients and detected a new subtype, 14i/a. We found that the proportion of 14i/a type in serofast patients was significantly higher than that in patients with serological cure, predicting an increasing risk of serofast status. Levels of chemerin were higher in the serum of serofast cases than serological cure cases, potentially indicating a novel cytokine marker for serofast in early syphilis patients after therapy. We hope that these results contribute to improve guidelines for the management of syphilis patients who experience serofast.

13 May 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
FDFang-Zhi Du
Fang-Zhi Du
HZHai-Ni Zhang
Hai-Ni Zhang
JLJing-Jing Li
Jing-Jing Li
ZZZhi-Ju Zheng
Zhi-Ju Zheng
XZXu Zhang
Xu Zhang
QWQianqiu Wang
Qianqiu Wang
Considered the increased threaten of neurosyphilis in China, a review on cases reported in the literature to describe the clinical epidemiological characteristics of neurosyphilis cases, may be beneficial to the early detection and management strategies of neurosyphilis for clinicians. We searched the literature on Chinese neurosyphilis cases published from January 1, 2009 to December 31, 2021, described their clinical epidemiological characteristics and calculated the prevalence of neurosyphilis amongst other associated diseases, according to the individual study criteria. A total of 284 studies including 7,486 neurosyphilis cases were included. No meta-analysis was performed due to the heterogeneity of the data. Among 149 case reports and 93 retrospective case series studies, the main clinical manifestation of 3,507 neurosyphilis cases was cerebral parenchymal syphilis (57.3%), followed by asymptomatic neurosyphilis (16.7%), meningovascular syphilis (13.6%), meningitis syphilis (7.7%) and ocular syphilis (2.8%), etc. In addition, the initial diagnosis was incorrect in 53.2% patients, and the most frequent misdiagnoses were mental disorders (31.0%), stroke (15.9%), cognitive impairment (9.0%), etc. The positive or abnormal rates of cerebrospinal fluid non-treponemal and treponemal tests, white blood cell counts and protein concentrations were 74.2%, 96.2%, 61.5%, and 60.9%, respectively. Aqueous penicillin was the first choice for treatment in 88.3% cases, and 81.7% and 50.0% patients had response in the improvement of symptoms and serological effective in CSF, respectively. Among 26 studies on neurosyphilis patients amongst other associated diseases, the prevalence of neurosyphilis amongst central nervous system infectious diseases, syphilis-associated neurological symptoms, serofast status, coinfected with human immunodeficiency virus were 10.6%–30.1%, 23.2%–35.5%, 9.8%–56.1%, and 8.9%, respectively. In summary, the lack of early detection of neurosyphilis cases remains a clinical challenge. The high rate of misdiagnosis and high prevalence of neurosyphilis amongst associated diseases strongly remind clinicians to focus on the early detection among suspected cases. Besides, the standard treatment regimen and long-term follow-up, which complied with guideline should be provided. Further prospective studies are urgent to better delineate the clinical epidemiological characteristics of neurosyphilis in China.

1 March 2020 in Experimental Cell Research
Verified
Journal Article
Closed access
WHWenlong Hu
Wenlong Hu
BXBufang Xu
Bufang Xu
JZJingping Zhang
Jingping Zhang
CKCaixia Kou
Caixia Kou
JLJinquan Liu
Jinquan Liu
RZRui-Li Zhang
Rui-Li Zhang

2 February 2019 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
BXBu-Fang Xu
Bu-Fang Xu
QWQianqiu Wang
Qianqiu Wang
JZJing-Ping Zhang
Jing-Ping Zhang
WHWen-Long Hu
Wen-Long Hu
RZRui-Li Zhang
Rui-Li Zhang

1 October 2022 in Trials
Verified
Journal Article
Open access
PDF file
FDFang-Zhi Du
Fang-Zhi Du
MWMin-Zhi Wu
Min-Zhi Wu
XZXu Zhang
Xu Zhang
RZRui-Li Zhang
Rui-Li Zhang
QWQianqiu Wang
Qianqiu Wang
Background: Neurosyphilis may cause irreversible neurological sequelae. First-line treatment consists of penicillin G, with ceftriaxone being an alternative treatment in patients allergic to penicillin. The lack of clinical data comparing the efficacy of these two drugs indicated the need for comparative clinical trials to improve national treatment guidelines in China. Methods/design: In this multicenter randomized controlled clinical trial, 290 patients newly diagnosed with neurosyphilis will be randomized 1:1 to treatment with aqueous crystalline penicillin G (ACPG) or ceftriaxone. Patients will be treated with standard regimens of ACPG or ceftriaxone according to Chinese National Guidelines and will be followed up for 12 months. All clinical parameters will be assessed at baseline and at follow-up 3, 6, 9, and 12 months later. The primary outcomes will include cerebrospinal fluid (CSF) white blood cell (WBC) count, serological efficacy, and clinical efficacy. The secondary outcomes will include CSF protein concentrations, Mini-Mental State Examination (MMSE) scores, imaging results, recurrence, and time to recovery from neurosyphilis. Adverse events will be monitored and recorded during the trial. Discussion: This trial will provide clinical data to determine whether ceftriaxone is non inferior to ACPG in treating neurosyphilis and will provide evidence for the improvement of treatment guidelines. Trial registration: Chinese Clinical Trial Registry ChiCTR2100047164. Registered on 9 June 2021 and updated on 23 November 2021.

19 July 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
RZRui-Li Zhang
Rui-Li Zhang
QWQianqiu Wang
Qianqiu Wang
LYLi‐Jia Yang
Li‐Jia Yang